Plasma fibrinogen: A new factor of the metabolic syndrome: A population- based study

Diabetes Care

Volumn 21, Issue 4, 1998, Pages 649-654

  Imperatore, Gluseppina ^a   Riccardi, Gabriele ^a   Iovine, Ciro ^a   Rivellese, Angela A ^a   Vaccaro, Olga ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERFIBRINOGENEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NORMAL HUMAN; OBESITY; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FASTING; FIBRINOGEN; HUMANS; INSULIN; INSULIN RESISTANCE; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; SMOKING; TRIGLYCERIDES;

EID: 0031897874     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.4.649     Document Type: Article

References (38)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome, Diabetologia 34:416-422, 1991
3. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956-963, 1993
4. Ganda PO, Arkin CF: Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 15:1245-1250, 1992
5. Valek J, Valkova L, Zuzana V, Topinka V: Increased fibrinogen levels in the offspring of hypertensive men: relation with hyperinsulinemia and the metabolic syndrome. Artenoscler Thromb Vase Biol 15:2229-2233, 1995
6. Facchini F, Chen YD, Clinkingbeard C: Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens 5:694-699, 1993
7. Juhan-Vague I, Thompson SG, Jespersen J, the ECAT Angina Pectoris Study Group: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris, Arterioscler Thromb 13:1865-1873, 1993
8. Feskens EJM, Kromhout D: Hyperinsulinemia, risk factors, and coronary heart disease: the Zutphen Elderly Study. Arterioscler Thromb 14:1641-1647, 1994
9. Folsom AR, Qamhhieh HT, Flack JM, Hilner JE, Liu K, Howaerd BV, Tracy RP for the investigators of the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Plasma fibrinogen levels and correlates in young adults. Am J Epidemiol 138:1023-1036, 1993
10. Eliasson M, Evrin PE, Lunblad D: Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICA Study. J Clin Epidemiol 47:513-524, 1994
11. Rose GA, Blackburn H, Gillum RF, Prineas RJ: Cardiovascular Survey Methods. 2nd ed. Geneva, World Health Org., 1982 (Monogr. Ser. No. 56)
12. Prineas RJ, Crow RS, Blackburn H: The Minnesota Code Manual of Electrocardiographs Findings. Littleton, MA, Wright, 1982
13. American Diabetes Association: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Committee Report). Diabetes Care 20:1183-1197, 1997
14. El-Deriny S, Ng RH, Statland BE: Evaluation of the Kodak Ektachem DT-60 Analyzer. Clin Chem 32:415-419, 1986
15. Kaufman HW, McNamara J, Anderson KM: How reliably can compact chemistry analyzers measure lipids? JAMA 263:1245-1249, 1990
16. Marotta G, Auletta P, Liguori M, Turbati M, Riccardi G, Vaccaro O: Uso della chimica a secco in una campagna per l'identificazione dei fattori di rischio cardiovascolare. Epidemiol Prev 18:194-245, 1994
17. Roth J, Gorden P: Clinical application of the insulin assay. In Methods in Investigative and Diagnostic Endocrinology. Berson SA, Yalow RS, Eds. Amsterdam, North Holland Publishing Company, 1973, p. 876-882
18. Fink PC, Romer M, Haeckel R, Fateh-Moghadam A, Delanghe J, Gressner AM, Dubs RW: Measurement of protein with the Behring nephelometer: a multicenter evaluation. J Clin Chem Clin Biochem 27:261-276, 1989
19. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. New York, Van Nostrand Reinhold, 1982, p. 419-446
20. Lee J: Covariate adjustment of rates based on the multiple logistic regression model. J Chronic Dis 34:415-426, 1981
21. Folsom AR, Kenneth KW, Davis CE, Conlan MG, Sorlie PD, Szklo M: Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91:191-205, 1991
22. Cigolini M, Targher G, De Sandre G, Muggeo M, Seidell JC: Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. Eur J Clin Invest 24:126-130, 1994
23. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D: Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 43:1579-1586, 1994
24. Beatty OL, Harper R, Sheridan B: Insulin resistance in offspring of hypertensive parents. BMJ 307:92-96, 1993
25. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278, 1990
26. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993
27. De Feo P, Volpi E, Lucidi P, Cruciani G, Reboldi G, Siepi D, Mannarino E, Santeusanio F, Brunetti P, Bolli G: Physiological increments in plasma insulin concentrations have selective effects on synthesis of hepatic proteins in normal humans. Diabetes 42:95-100, 1993
28. Lewis GF, Uffelman KD, Szeto LW, Steiner G: Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apolipoprotein (apo) B production in normal weight and obese individuals. Diabetes 42:833-842, 1993
29. Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215:9-32, 1994
30. Mohamed-Ali V, Gould MM, Gillies S, Goubet S, Yudkin JS, Haines JP: Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role of insulin. Diabetologia 38;1110-1116, 1995
31. Facchini FS, Hollenbeck CB, Jeppesen J, Chen IYD, Reaven GM: Insulin resistance and cigarette smoking. Lancet 339:1128- 1130, 1992
32. Haffner SM: The insulin resistance syndrome revisited. Diabetes Care 19:275-277, 1996
33. Vanninen E, Laitinen J, Uusitupa M: Physical activity and fibrinogen concentration in newly diagnosed NIDDM. Diabetes Care 17:1031-1038, 1994
34. Folsom AR, Quamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscl Thromb 13:162-169, 1993
35. De Boever E, De Bacquer D, Baele G, Rosseneu M, De Backer G: Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol 5:915-921, 1995
36. Ditschuneit HH, Flechtner-Mors M, Adler G: Fibrinogen in obesity before and after weight reduction. Obes Res 3:43-48, 1995
37. Ernst E: Does the reduction of body weight lower plasma fibrinogen levels? BMJ 70:116-118, 1993
38. Svedsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K: Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 16:382-385, 1996